Physician profile
Thomas Yang Sun
NPI 1215468160
$378.05
in general payments reported to CMS, 2019-2025
15 companies · $83.60 in 2025
The $83.60 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.55 · 2023: $118 · 2024: $156 · 2025: $83.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $327 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.85 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $47.17 | 2024 | Ogsiveo |
| Pfizer INC. | $30.65 | 2025 | |
| Daiichi Sankyo INC. | $28.68 | 2023 | |
| Abbvie INC. | $27.82 | 2025 | |
| Seagen INC. | $27.67 | 2023 | Tukysa |
| E.R. Squibb & Sons, L.L.C. | $25.64 | 2024 | Opdivo |
| Celgene Corporation | $25.61 | 2024 | |
| Teleflex LLC | $25.13 | 2025 | Arrow |
| Stemline Therapeutics INC. | $22.94 | 2023 | Orserdu |
| Neurocrine Biosciences, INC. | $20.55 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.47 | 2024 | Ninlaro |
| Glaxosmithkline, LLC. | $20.07 | 2023 | Ojjaara |
| Gilead Sciences, INC. | $19.39 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $18.53 | 2023 | Imbruvica, Epkinly |
| Adc Therapeutics America, INC. | $17.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Yang Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.